Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817940 | 0.76 | KMT2A (0.51) | PDE4BPDE4DKMT2ASTAT3LMNA | |
| SCHEMBL2208368 | 0.74 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL17338019 | 0.73 | PDE4B (0.68) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL28743782 | 0.71 | KMT2A (0.45) | PDE4BPDE4DKMT2ASTAT3TBXAS1 | |
| SCHEMBL1520240 | 0.70 | TBXAS1 (0.64) | KMT2ASTAT3TBXAS1ALDH1A1KDM4E | |
| SCHEMBL28101197 | 0.70 | CCNE2 (0.53) | KMT2A | |
| SCHEMBL10091947 | 0.70 | ATM (0.60) | ROCK1ATMNPSR1LMNAALDH1A1 | |
| SCHEMBL30834686 | 0.69 | CCNE2 (0.71) | KMT2A | |
| SCHEMBL11895927 | 0.69 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL24199376 | 0.69 | KMT2A (0.61) | KMT2ASTAT3TBXAS1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981912-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-7601749-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1805171-A4 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090111867-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7476667-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405215-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1805171-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | ATHERSYS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006034419-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | PTGDR2, TBXA2R, HCAR2 | PDE4A 1110/4885PDE4B 1313/4885PDE4C 1673/4885 |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | PDE4A 1110/4885PDE4B 1313/4885PDE4C 1673/4885 |
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | PDE4A 1110/4885PDE4B 1313/4885PDE4C 1673/4885 |
| US-20090111867-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | PDE4A 1110/4885PDE4B 1313/4885PDE4C 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.